Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00822926 · ClinicalTrials.gov registry record · NA

Subcutaneous Botulinum Toxin for Cutaneous Allodynia - Enriched Responder Trial

A NA study, sponsored by Stanford University.

Terminated
Registry status
NA
Development phase
5
Enrollment target

NCT00822926: Clinical Trial NA study, sponsored by Stanford University.

NCT00822926 is a NA study that was terminated before completion, run by Stanford University. The registered enrollment target is 5 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00822926, a NA study, was terminated before completion, sponsored by Stanford University.

TERMINATED
Registry status
NA
Development phase
5 participants
Enrollment target

Study Summary

Superficial injection of Botulinum toxin has been advocated for cosmetic purposes but has also been reported to be helpful for some pain conditions. The investigators have observed prolonged profound analgesia following subcutaneous superficial injection of Botulinum Toxin Type A (BTA) in patients with certain types of neuropathic pain. the investigators propose to study if addition of BTA extends pain relief compared to placebo when injected subcutaneously into areas of cutaneous allodynia (the property that a normally non-noxious stimulus is perceived as painful).

Primary Outcome

Participants completed the Pain Numeric Rating Scale everyday after the injections. Outcome measure represents the number of days before pain returned to baseline levels.

Interventions

  • DRUG Saline
  • DRUG Botulinum Toxin Type A

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2009-01
Est. Completion 2013-12
Phase NA
Stanford University

1,744 total trials

Why NCT00822926 stopped before completion

NCT00822926 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).

The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.

NCT00822926 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00822926 about?

NCT00822926 is a clinical study titled "Subcutaneous Botulinum Toxin for Cutaneous Allodynia - Enriched Responder Trial". Superficial injection of Botulinum toxin has been advocated for cosmetic purposes but has also been reported to be helpful for some pain conditions. The investigators have observed prolonged profound analgesia following subcutaneous superficial injection of Botulinum Toxin Type A (BTA) in patients w...

What is the current status of trial NCT00822926?

This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2009-01. Estimated completion is 2013-12.

What interventions are being tested in trial NCT00822926?

The interventions under investigation include: Saline (DRUG), Botulinum Toxin Type A (DRUG).

Who is sponsoring clinical trial NCT00822926?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00822926's enrollment target sits among peer trials

5 1988th of 2000 higher than 5 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00822926, the US trial registry maintained by the National Library of Medicine. NCT00822926 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.